Schaar Cees G, Vermeer Henricus J, Wijermans Pierre W, Huisman Wim, le Cessie Saskia, Kluin-Nelemans Hanneke C
Haematologica. 2005 Oct;90(10):1437-8.
Serum syndecan-1 was investigated in 189 patients with newly diagnosed monoclonal proteinemia [the diagnoses were multiple myeloma (66), monoclonal gammopathies of undetermined significance (MGUS; n=54), provisional MGUS (no bone marrow examination performed; n=69)] and 36 controls. Syndecan-1 levels ranged widely between all diagnostic categories and were of limited discriminatory value (sensitivity 68%, specificity 78%) in patients with newly diagnosed monoclonal proteinemia.
